BayCom (BCML) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for June 17, 2025, to elect nine directors, hold an advisory vote on executive compensation, and ratify the appointment of Moss Adams LLP as auditor for 2025.
Shareholders can vote via Internet, mail, or in person, with cumulative voting rights available for director elections if notice is given.
Proxy materials are distributed electronically to reduce costs and environmental impact, with printed copies available upon request.
Voting matters and shareholder proposals
Proposals include electing nine directors for one-year terms, a non-binding say-on-pay vote, and ratification of Moss Adams LLP as auditor.
Shareholders may submit director nominations and proposals following specific advance notice and information requirements.
The board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of nine members with diverse backgrounds; three are women, and several identify with minority groups.
Board committees include Audit, Compensation, and Corporate Governance and Nominating, all composed of independent directors.
The board separates the roles of CEO and Chairman and emphasizes director independence and diversity.
Directors are expected to attend annual meetings, and all attended the previous year.
Latest events from BayCom
- Q4 2025 earnings grew 37% sequentially on higher net interest income and lower credit loss provisions.BCML
Q4 202522 Jan 2026 - Annual meeting to vote on directors, executive pay, and auditor, with online proxy access.BCML
Proxy Filing2 Dec 2025 - Earnings declined on higher credit loss provisions, but capital and liquidity remain strong.BCML
Q3 20257 Nov 2025 - Q2 2024 net income fell 22% as margins compressed, but capital and deposits remained strong.BCML
Q2 202414 Oct 2025 - Earnings and net interest margin improved, with robust capital and higher nonperforming loans.BCML
Q2 202511 Aug 2025 - Q3 net loss widened to $16.8M; $182.2M cash on hand supports clinical pipeline into 2027.BCML
Q3 202413 Jun 2025 - Q1 2025 net income was $5.7M, with margin gains and robust capital ratios despite higher provisions.BCML
Q1 20256 Jun 2025 - Q4 2024 saw stable earnings, margin improvement, and strong credit quality at BayCom Corp.BCML
Q4 20245 Jun 2025